Watch and Wait Approach for Rectal Cancer Following Neoadjuvant Treatment: The Experience of a High Volume Cancer Center.
MRI
no operative management
rectal cancer
rectal sparing
watch and wait
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
21 Aug 2021
21 Aug 2021
Historique:
received:
21
06
2021
revised:
07
08
2021
accepted:
08
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Multimodal treatments for rectal cancer, along with significant research on predictors to response to therapy, have led to more conservative surgical strategies. We describe our experience of the rectal sparing approach in rectal cancer patients with clinical complete response (cCR) after neoadjuvant treatment. We also specifically highlight our clinical and imaging criteria to select patients for the watch and wait strategy (w&w). Data came from 39 out of 670 patients treated for locally advanced rectal cancer between January 2016 until February 2020. The selection criteria were a clinical complete response after neoadjuvant chemotherapy managed with a watch and wait (w&w) strategy. A strict follow-up period was adopted in these selected patients and follow-ups were performed every three months during the first two years and every six months after that. The median follow-up time was 28 months. Six patients had a local recurrence (15.3%); all were salvageable by total mesorectal excision (TME). Five patients had a distant metastasis (12.8%). There was no local unsalvageable disease after w&w strategy. The rectal sparing approach in patients with clinical complete response after neoadjuvant treatment is the best possible treatment and is appropriate to analyze from this perspective. The watch and wait approach after neoadjuvant treatment for rectal cancer can be successfully explored after inflexible and strict patient selection.
Identifiants
pubmed: 34441441
pii: diagnostics11081507
doi: 10.3390/diagnostics11081507
pmc: PMC8394713
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Surg. 2007 Sep;246(3):481-8; discussion 488-90
pubmed: 17717452
Radiol Med. 2019 Jul;124(7):671-681
pubmed: 30806918
Tech Coloproctol. 2017 Aug;21(8):633-640
pubmed: 28755256
Surg Endosc. 2018 Jul;32(7):3234-3246
pubmed: 29344789
J Clin Oncol. 2018 Mar 1;36(7):674-681
pubmed: 29346040
Radiol Med. 2020 Jun;125(6):522-530
pubmed: 32020526
Dis Colon Rectum. 2019 Jan;62(1):33-39
pubmed: 30451761
Radiol Med. 2021 Mar;126(3):421-429
pubmed: 32833198
Eur J Surg Oncol. 2005 Sep;31(7):735-42
pubmed: 16180267
Ann Surg. 2018 Dec;268(6):955-967
pubmed: 29746338
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565
PLoS One. 2016 Aug 22;11(8):e0160732
pubmed: 27548058
Colorectal Dis. 2016 Mar;18(3):234-46
pubmed: 26531759
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
Colorectal Dis. 2018 Jul;20(7):574-585
pubmed: 29582537
Cancers (Basel). 2020 Dec 03;12(12):
pubmed: 33287114
Expert Rev Anticancer Ther. 2021 May;21(5):489-500
pubmed: 33356679
Lancet Oncol. 2016 Feb;17(2):174-183
pubmed: 26705854
Radiat Oncol. 2021 Jan 19;16(1):16
pubmed: 33468176
Radiol Med. 2021 Aug;126(8):1044-1054
pubmed: 34041663
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Radiol Med. 2020 Dec;125(12):1216-1224
pubmed: 32410063
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Lancet. 2018 Jun 23;391(10139):2537-2545
pubmed: 29976470
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):501-513
pubmed: 28479372
Lancet Oncol. 2021 Jan;22(1):43-50
pubmed: 33316218
JAMA Oncol. 2019 Apr 1;5(4):e185896
pubmed: 30629084
Radiol Med. 2020 Oct;125(10):990-998
pubmed: 32277332
Int J Colorectal Dis. 1997;12(1):19-23
pubmed: 9112145
J Natl Cancer Inst. 2016 Aug 10;108(12):
pubmed: 27509881
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005